OmniAb, Inc., a biotech company operating within the health care sector, has recently reported a significant change in ownership involving its Chief Operating Officer, Amechi Ekeke. This development was disclosed in a Form 4 filing submitted to the Securities and Exchange Commission (SEC) on August 3, 2026. The filing details the exercise of a stock-option grant that became active on August 1, 2026, allowing Ekeke to acquire a substantial block of the company’s common shares.
The transaction involved the exercise of stock options rather than a purchase at market price, indicating a strategic move by the officer to increase direct ownership in OmniAb, Inc. The options exercised cover a significant portion of the company’s shares, reflecting a notable increase in Ekeke’s stake. The terms of the option grant include a vesting schedule that extends to August 2026, contingent upon continued service to the company. This vesting schedule is designed to align the officer’s interests with the long-term success of OmniAb, Inc.
OmniAb, Inc. specializes in therapeutic antibody discovery, providing access to diverse antibody repertoires and high-throughput screening technologies. These services are crucial for pharmaceutical industry partners, enabling the discovery of next-generation therapeutics. As a key player in the health care sector, OmniAb serves biopharmaceutical companies and research institutions worldwide. The company’s stock is traded on the Nasdaq, with a close price of $2.03 as of August 4, 2026. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $2.79 on May 31, 2026, and a 52-week low of $1.30 on November 4, 2025. The current market capitalization stands at approximately $298.64 million USD.
This recent change in ownership by a high-ranking executive underscores the confidence in OmniAb, Inc.’s strategic direction and future prospects. The company continues to focus on its core mission of advancing therapeutic antibody discovery, leveraging its expertise to support the development of innovative treatments. For more detailed information about OmniAb, Inc. and its activities, stakeholders and interested parties are encouraged to visit the company’s website at www.omniab.com .
